New drug combo aims to tame rare blood cancer
NCT ID NCT07357727
Summary
This study is testing whether adding a new drug called pelabresib to the standard treatment (ruxolitinib) works better than the standard treatment alone for adults with myelofibrosis, a rare bone marrow cancer. Researchers will measure if the combination reduces spleen size and improves symptoms like fatigue and pain. The trial is enrolling 460 participants who have not previously taken JAK inhibitor medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS (PMF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGSeoul, 03080, South Korea
Conditions
Explore the condition pages connected to this study.